The cancer diagnostics company BiBBInstruments AB (“BiBB” or “the Company”), which develops EndoDrill® – the world’s first CE-marked electric-driven biopsy instrument for endoscopy – announces that EndoDrill® GI has been successfully used in a live broadcasted biopsy procedure on a patient in Porto, Portugal. The sampling of a pancreatic tumor was performed at Hospital Pedro Hispano and broadcast live – the ultimate test for a new device – during the annual meeting of the Portuguese Society of Gastrointestinal Endoscopy, Live Sped 2025.
“It is encouraging to see how well the EndoDrill® GI fits into current clinical workflow and its efficacy in obtaining high-quality biopsies,” says Dr. Charles Walther, founder and CMO of BiBB.
BiBB’s team was present when Dr. Francisco Baldaque Silva, Head of Gastroenterology at Hospital Pedro Hispano in Porto and Senior Consultant at Karolinska University Hospital (KS) in Stockholm, performed a patient case during the Portuguese annual meeting Live Sped 2025. Patient cases broadcast live to a broad user group constitute the ultimate test for a new medtech device, as both its pros and cons are ruthlessly revealed in real-time. The live biopsy procedure with EndoDrill® GI was successful, and both the team and the audience in the well-filled room provided great feedback and expressed their appreciation for the visible, high-quality core biopsies that the procedure resulted in. The live biopsy procedure was suggested by Dr. Baldaque Silva after he had the opportunity to use EndoDrill® GI both at KS and at Hospital Pedro Hispano.
About EndoDrill® GI
EndoDrill® GI is the world’s first CE-marked electric-driven biopsy instrument for endoscopic ultrasound (EUS). The instrument is used for EUS-guided tissue sampling in various indications within the gastrointestinal tract, such as the pancreas, stomach, esophagus, lymph nodes, and liver. EndoDrill® GI received FDA 510(k) clearance in the United States in 2023 and CE approval in Europe in early 2024. The product is currently undergoing clinical evaluation in both the United States and Europe. The commercialization phase began in early 2025, when the first order was received from a university hospital in the United States.
This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.
For more information about BiBB, please contact:
Fredrik Lindblad, CEO
E-mail: fredrik.lindblad@bibbinstruments.com
Phone: +46 70 899 94 86
www.bibbinstruments.com
About BiBB
The cancer diagnostics company BiBBInstruments AB develops and manufactures EndoDrill®, a patented product line of electric-driven endoscopic biopsy instruments. The EndoDrill® instruments take high-quality tissue samples with high precision with the goal of improving the diagnosis of several serious cancers, such as stomach, pancreas, liver, lung, and bladder. The product portfolio is aimed at the global market for ultrasound-guided endoscopic (EUS/EBUS) biopsy instruments, which constitute the most advanced and fast-growing area of endoscopy. BiBB received 510(k) clearance from the US FDA for the lead product EndoDrill® GI in 2023. At the beginning of 2024, CE marking according to MDR was also obtained for all three product variants: EndoDrill® GI, EndoDrill® EBUS and EndoDrill® URO. Thus EndoDrill® is the first cleared powered endoscopic biopsy system in both the US and Europe. The EndoDrill® system includes sterile disposable biopsy instruments with associated drive system. The company was founded in 2013 by Dr. Charles Walther, cancer researcher at Lund University and senior consultant in clinical pathology at Skåne University Hospital in Lund. BiBBInstruments is based at Medicon Village in Lund and the BiBBInstruments share (ticker: BIBB) is listed on Spotlight Stock Market.